Advertisement

Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm

  • Adam B. Weiner
  • Oluwarotimi S. Nettey
  • Alicia K. MorgansEmail author
Genitourinary Cancers (S Gupta, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Genitourinary Cancers

Opinion statement

Combination systemic therapy is now standard of care for all men with metastatic, hormone-sensitive prostate cancer (mHSPC). Patients with mHSPC should be treated with standard androgen deprivation therapy (ADT) and abiraterone acetate with prednisone or docetaxel (chemohormoanl therapy) unless there are contraindications to combination therapy. Based on the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) study subgroup analysis, chemohormonal therapy may be most beneficial in men with high-volume disease burden, as men with low-volume metastatic disease do not appear to experience a survival benefit with chemohormonal therapy, while abiraterone in combination with ADT appears to be beneficial across both disease volume subgroups. Decisions regarding whether to use chemohormonal therapy or abiraterone and ADT for men with mHSPC should integrate consideration of volume of disease burden, quality of life effects, duration of therapy, and patient preferences for treatment as there is no formally powered prospective head-to-head comparison of these options demonstrating superiority of one approach over the other. Treatment of the primary tumor with radiation should be considered in men with de novo low-volume metastatic disease as radiation is associated with prolonged survival and a tolerable toxicity profile. Men with de novo high-volume metastatic disease do not appear to have improved survival with radiation of the primary tumor. Numerous clinical trials are ongoing to evaluate treatment approaches that may benefit men with mHSPC. Radical prostatectomy in men with mHSPC in combination with optimal systemic therapy is currently being assessed in a clinical trial, but should not be considered outside of a clinical trial. Metastasis-directed therapy with radiotherapy directed at metastatic lesions is still investigational, but can be considered in clinical trials in men with oligometastatic disease. Multiple studies are enrolling worldwide for men with mHSPC, and these should be considered for all interested patients.

Keywords

Prostatic neoplasm Metastatic Therapeutics Hormone sensitive Treatment outcomes Review 

Notes

Compliance with Ethical Standards

Conflict of Interest

Adam B. Weiner declares that he has no conflict of interest. Oluwarotimi S. Nettey declares that she has no conflict of interest. Alicia K. Morgans has received research funding (paid to her institution) from Bayer, and has received compensation for service on advisory boards from Astellas, Bayer, Sanofi, Genentech, AstraZeneca, and Janssen; has received compensation for service as a consultant from AstraZeneca; has received compensation for non-branded talks for education from Astellas; and has received compensation for research collaboration from Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.Google Scholar
  2. 2.
    Dall’Era MA, deVere-White R, Rodriguez D, Cress R. Changing incidence of metastatic prostate cancer by race and age, 1988–2015. Eur Urol Focus. 2018; In pressGoogle Scholar
  3. 3.
    Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016;19(4):395–7.PubMedGoogle Scholar
  4. 4.
    Faiena I, Holden S, Cooperberg MR, et al. Prostate cancer screening and the goldilocks principle: how much is just right? J Clin Oncol. 2018;36(10):937–41.PubMedGoogle Scholar
  5. 5.
    Force USPST, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–13.Google Scholar
  6. 6.
    Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253–61.PubMedGoogle Scholar
  9. 9.
    Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815–25.PubMedGoogle Scholar
  10. 10.
    Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedGoogle Scholar
  11. 11.
    Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedGoogle Scholar
  12. 12.
    Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.PubMedGoogle Scholar
  13. 13.
    •• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51 One of two large randomized controlled trials demonstrating the survival benefits of abiraterone in addition to androgen deprivations.Google Scholar
  14. 14.
    •• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77 One of two large randomized controlled trials demonstrating the survival benefits of docetaxel with androgen deprivations in men with metastatic hormone sensitive prostate cancer, specifically in men with high burden of metastatic disease.Google Scholar
  15. 15.
    Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.PubMedPubMedCentralGoogle Scholar
  16. 16.
    • Boeve LMS, Hulshof M, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD Trial. Eur Urol. 2019;75(3):410–18.Google Scholar
  17. 17.
    Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? V. Eur Urol. 2014;65(6):1058–66.PubMedGoogle Scholar
  18. 18.
    •Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.Google Scholar
  19. 19.
    • Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase ii trial. J Clin Oncol. 2018;36(5):446 Randomized trial suggesting metastasis directed therapy could delay the need for androgen deprivation therapy in men with metastatic prostate cancer.Google Scholar
  20. 20.
    Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2018. In press.Google Scholar
  21. 21.
    Zattoni F, Nehra A, Murphy CR, et al. Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy. Eur Urol Focus. 2016;2(5):522–31.PubMedGoogle Scholar
  22. 22.
    Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35(5):504–9.PubMedGoogle Scholar
  23. 23.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–903.PubMedGoogle Scholar
  24. 24.
    Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24.PubMedGoogle Scholar
  25. 25.
    Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Mason MD, Clarke NW, James ND, et al. Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. J Clin Oncol. 2017;35(14):1530.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(1):8–10.Google Scholar
  28. 28.
    Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202.PubMedGoogle Scholar
  29. 29.
    •• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080–7 Long-term follow-up of one of two large randomized controlled trials demonstrating the survival benefits of docetaxel with androgen deprivations in men with metastatic hormone sensitive prostate cancer, specically in men with high burden of metastatic disease.Google Scholar
  30. 30.
    Graziani T, Ceci F, Castellucci P, et al. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43(11):1971–9.PubMedGoogle Scholar
  31. 31.
    Nanni C, Schiavina R, Brunocilla E, et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015;40(8):e386–91.PubMedGoogle Scholar
  32. 32.
    Lake ST, Greene KL, Westphalen AC, et al. Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017;7(1):77.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440–8.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822–32.PubMedGoogle Scholar
  35. 35.
    Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–18.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.PubMedGoogle Scholar
  37. 37.
    Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.PubMedGoogle Scholar
  39. 39.
    Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.PubMedGoogle Scholar
  40. 40.
    Gao YF, He WY, He XY, Huang YL, Gou X. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy An update meta-analysis. Medicine. 2017;96(27): e7368PubMedPubMedCentralGoogle Scholar
  41. 41.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–6.PubMedGoogle Scholar
  42. 42.
    Serpa Neto A, Tobias-Machado M, Esteves MA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36–44.PubMedGoogle Scholar
  43. 43.
    Alibhai SMH, Zukotynski K, Walker-Dilks C. Bone health and bone-targeted therapies for nonmetastatic prostate cancer RESPONSE. Ann Intern Med. 2018;168(6):459.PubMedGoogle Scholar
  44. 44.
    Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 ( Alliance). J Clin Oncol. 2014;32(11):1143.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Gralow JR, Biermann JS, Farooki A, et al. NCCN Task force report: bone health in cancer care. J Natl Compr Cancer Netw. 2013;11(Suppl 3):S1–50 quiz S51.Google Scholar
  46. 46.
    Raber J, Bongers G, LeFevour A, Buttini M, Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci. 2002;22(12):5204–9.PubMedGoogle Scholar
  47. 47.
    Ramsden M, Nyborg AC, Murphy MP, et al. Androgens modulate beta-amyloid levels in male rat brain. J Neurochem. 2003;87(4):1052–5.PubMedGoogle Scholar
  48. 48.
    Gunlusoy B, Ceylan Y, Koskderelioglu A, et al. Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer. Urology. 2017;103:167–72.PubMedGoogle Scholar
  49. 49.
    Alibhai SM, Timilshina N, Duff-Canning S, et al. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer. 2017;123(2):237–44.PubMedGoogle Scholar
  50. 50.
    Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26(36):5936–42.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.PubMedGoogle Scholar
  52. 52.
    Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70(2):256–62.PubMedGoogle Scholar
  53. 53.
    Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Sathianathen NJ, Philippou YA, Kuntz GM, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018;10:CD012816.Google Scholar
  55. 55.
    Morgans AK, Chen YH, Sweeney CJ, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018;36(11):1088–95.PubMedPubMedCentralGoogle Scholar
  56. 56.
    •• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60 One of two large randomized controlled trials demonstrating the survival benefits of abiraterone in addition to androgen deprivations.PubMedGoogle Scholar
  57. 57.
    Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88–101.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Hoyle AP, Ali SA, James ND, et al. Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Annals of Oncology. 2018;29:722.Google Scholar
  59. 59.
    Chi KN, Protheroe A, Rodriguez-Antolin A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194–206.PubMedGoogle Scholar
  60. 60.
    Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–48.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. J Clin Oncol. 2019;37(7_suppl):687.Google Scholar
  62. 62.
    Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN study unblinded as dual primary endpoints achieved in clinical program evaluating treatment of patients with metastatic castration-sensitive prostate cancer. 2019. https://www.jnj.com/janssen-announces-erleada-apalutamide-phase-3-titan-study-unblinded-as-dual-primary-endpoints-achieved-in-clinical-program-evaluating-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer. Accessed May 9, 2019.
  63. 63.
    Attard G, Sydes MR, Mason MD, et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014;66(5):799–802.PubMedGoogle Scholar
  64. 64.
    Gillessen S, Gilson C, James N, et al. Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur Urol. 2016;70(6):906–8.PubMedGoogle Scholar
  65. 65.
    Gilbert DC, Duong T, Sydes M, et al. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018;121(5):680–3.PubMedGoogle Scholar
  66. 66.
    Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7.PubMedPubMedCentralGoogle Scholar
  67. 67.
    McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994–1005.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–11.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301–8.PubMedGoogle Scholar
  70. 70.
    Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194(2):378–85.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(24):2835–42.Google Scholar
  72. 72.
    Loppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol. 2017;72(1):14–9.PubMedGoogle Scholar
  73. 73.
    Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77(6):559–72.PubMedGoogle Scholar
  74. 74.
    Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.PubMedGoogle Scholar
  75. 75.
    Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018;1(1):46–53.PubMedGoogle Scholar
  76. 76.
    Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76(2):326–32.PubMedGoogle Scholar
  77. 77.
    De Bleser E, Tran PT, Ost P. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer. Curr Opin Urol. 2017;27(6):587–95.PubMedGoogle Scholar
  78. 78.
    Rischke HC, Schultze-Seemann W, Wieser G. et al. Strahlenther Onkol. 2015;191(4):310–20.PubMedGoogle Scholar
  79. 79.
    Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15(4):e623–32.PubMedGoogle Scholar
  80. 80.
    Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol. 2016;28(9):e115–20.Google Scholar
  81. 81.
    Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.PubMedGoogle Scholar
  82. 82.
    Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.PubMedGoogle Scholar
  84. 84.
    Fossati N, Suardi N, Gandaglia G, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2018;75(1):176–83.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Adam B. Weiner
    • 1
  • Oluwarotimi S. Nettey
    • 1
  • Alicia K. Morgans
    • 2
    Email author
  1. 1.Department of UrologyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations